C4X Discovery Holdings PLC Clive Dix wins OBN Special Recognition Award
November 26 2021 - 5:19AM
RNS Non-Regulatory
TIDMC4XD
C4X Discovery Holdings PLC
26 November 2021
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
C4X Discovery CEO, Clive Dix, receives OBN Special Recognition
Award 2021
26 November 2021 - C4X Discovery Holdings plc (AIM: C4XD), is
honoured to announce that CEO, Dr Clive Dix has received the
Special Recognition Award at the OBN 2021 Awards for his life-long
contribution to the UK life sciences industry.
Eva-Lotta Allan, Chairman of C4X Discovery, commented: "The
prestigious OBN Awards celebrate the very best of UK life science.
We are therefore very proud of all that Clive has achieved
throughout his career, and in particular, here at C4XD. Clive is a
veteran of the UK biotechnology industry with more than 30 years of
experience, with a strong track record as a serially successful
entrepreneur and an experienced pharmaceutical R&D executive.
He has the scientific expertise, industry experience and leadership
qualities that are needed to grow companies in such a challenging
industry. Over the past year, in addition to his corporate work,
Clive has played a leading role in the UK Vaccine Taskforce which
has been recognised as leading one of the most successful rollouts
of the COVID-19 vaccination globally. Clive is an inspiration to us
here at C4XD and it is wonderful to see the recognition across the
industry for all his contributions to our thriving life sciences
sector."
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world--leading medicines, which
are developed by our partners for the benefit of patients. We have
a highly valuable and differentiated approach to Drug Discovery
through our enhanced DNA-based target identification and candidate
molecule design capabilities, generating small molecule drug
candidates across multiple disease areas including inflammation,
neurodegeneration, oncology and addictive disorders . Our
commercially attractive portfolio ranges from early stage novel
target opportunities to late stage Drug Discovery programmes ready
for out-licensing to partners and we have two commercially
partnered programmes with one candidate in clinical
development.
We collaborate with leading pharmaceutical and life sciences
companies to enrich our expertise and take our assets through
pre-clinical and clinical development. Through early-stage
revenue-generating licensing deals, we realise returns from our
high value pre-clinical assets which are reinvested to maximise the
value of our Drug Discovery portfolio. For more information visit
us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery
.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAMZMZMGVNGMZM
(END) Dow Jones Newswires
November 26, 2021 05:19 ET (10:19 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Sep 2024 to Oct 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Oct 2023 to Oct 2024